ForumIAS LATEST
- 15 Sept. | Current Affairs Pre-cum-Mains 2027 Morning 11 AM batch starts from 15th Sept. Click Here to Read More →
- 14 Sept. | Forum Residential Coaching (FRC) for UPSC preparation Click Here to know more →
- 14 Sept. | GS Advance Program (GSAP) for UPSC 2027 Mains starts from 14th Sept. Click Here to Read More →
News: In August 2026, intismeran, a personalised mRNA vaccine, showed reduced melanoma recurrence when combined with pembrolizumab.
About Melanoma

- Melanoma is a type of skin cancer.
- It develops from melanocytes, the cells that produce melanin.
- It usually develops on sun-exposed skin, including the arms, back, face and legs.
- In India, it commonly occurs on the soles of the feet or beneath the nails and is called acral lentiginous melanoma.
- Mucosal melanoma starts in the mucous membranes and is highly aggressive, with few early warning signs.
- Causes:
- UV Exposure: Most melanomas are caused by exposure to ultraviolet (UV) light from sunlight or tanning lamps and beds.
- Unclear Cause: The exact cause of all melanomas is not clear.
- Symptoms:
- Mole Changes: A change in an existing mole can be a warning sign.
- New Growth: A new pigmented or unusual-looking growth may develop on the skin.
- Persistent Lesions: Any pigmented lesion that changes or persists needs investigation.
- Treatment:
- Surgery: In early stages, surgery has a high probability of curing melanoma.
- Lymphadenectomy: If melanoma has spread, nearby lymph nodes may need to be removed.
- Metastasectomy: It is used to remove small melanoma growths from organs.
- Immunotherapy: Immune-checkpoint blockade using therapies targeting CTLA–4 (Cytotoxic T-Lymphocyte-Associated Protein4) and PD-1 (Programmed Cell Death Protein 1) can help the immune system attack tumours.
- Precision medicine: Next-generation sequencing (NGS) can identify tumour mutations, including BRAF pathway mutations, to guide targeted treatment.
- TIL therapy: Tumour-infiltrating lymphocytes (TILs) are taken from the tumour, expanded in the laboratory and reinfused in larger numbers.
- Personalised mRNA vaccine: In August 2026, intismeran with pembrolizumab significantly reduced recurrence after surgery, although survival data remain pending.



